Group 1 - The core viewpoint of the article is that Yibai Pharmaceutical (600594) is expected to report a net profit loss of between 285 million yuan and 342 million yuan for the year 2025 [1] - The company anticipates a 14% decline in revenue due to reduced sales of its main products [1] - Although the company's cost expenses are expected to decrease by 18%, the total cost expenses will still exceed revenue, leading to the projected loss [1] Group 2 - The financial department of the company plans to recognize an impairment provision for goodwill between 110 million yuan and 132 million yuan based on preliminary impairment testing results [1] - This impairment provision is expected to further increase the company's losses for the period [1]

Core Viewpoint - Yibai Pharmaceutical (600594.SH) is expected to report a net loss attributable to shareholders of the parent company ranging from -342 million to -285 million yuan for the fiscal year 2025, indicating a significant downturn in financial performance [1] Group 1: Financial Performance - The company's main product sales have decreased, leading to an anticipated revenue decline of 14% [1] - Although the company's cost expenses are expected to decrease by 18%, the total cost expenses will still exceed revenue, resulting in a loss for the period [1] Group 2: Impairment and Accounting - Based on preliminary impairment testing results, the financial department anticipates recognizing goodwill impairment provisions between 110 million and 132 million yuan, which will further increase the company's losses [1]

Core Viewpoint - Yibai Pharmaceutical (600594.SH) is expected to report a net loss attributable to shareholders of the parent company ranging from -342 million to -285 million yuan for the fiscal year 2025, indicating a significant downturn in financial performance [1] Financial Performance - The company's main product sales have decreased, leading to an anticipated revenue decline of 14% [1] - Although the company's cost expenses are expected to decrease by 18%, the total cost expenses will still exceed revenue, resulting in a net loss for the period [1] Impairment and Provisions - Based on preliminary impairment testing results, the financial department anticipates recognizing goodwill impairment provisions between 110 million and 132 million yuan, which will further increase the company's losses [1]

Core Viewpoint - The company Yibai Pharmaceutical (600594.SH) is expected to report a significant loss in 2025, with projected net profit attributable to shareholders ranging from -342 million to -285 million yuan [1] Financial Performance - The company anticipates a decline in revenue by 14% due to reduced sales of its main products [1] - Despite an expected decrease in costs and expenses by 18%, the total costs will still exceed revenue, leading to the projected losses [1] - The net profit after deducting non-recurring gains and losses is estimated to be between -336 million and -280 million yuan [1]

Core Viewpoint - Yibai Pharmaceutical announced a profit warning for the fiscal year 2025, expecting a net loss attributable to shareholders of between 285 million to 342 million yuan, indicating a significant deterioration compared to a loss of 317.22 million yuan in the same period last year [1] Financial Performance - The company anticipates a decline in revenue due to reduced sales of its main products [1] - Although costs have decreased, they remain higher than revenue, contributing to the expected losses [1] - The company plans to recognize an impairment provision for goodwill between 110 million to 132 million yuan, which will further exacerbate the losses [1]